Stock Events

Stock Events

Cyclerion Therapeutics 

$31.61
19
+$7.67+32.04% Monday 19:59

Statistics

Day High
23.52
Day Low
2.82
52W High
59.36
52W Low
2.82
Volume
435,847
Avg. Volume
7,300
Mkt Cap
1.44B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
Next
-3.42
-2.32
-1.21
-0.11
Expected EPS
-0.916192
Actual EPS
N/A

Financials

-170.11%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.07MRevenue
-3.53MNet Income

Analyst Ratings

$56.50Average Price Target
The highest estimate is 70.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYCN. It's not an investment recommendation.
NVIDIA
5
NVDA
Palantir Technologies
5
PLTR
Apple
4
AAPL
Amazon
4
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axsome Therapeutics
AXSM
Mkt Cap10.22B
Axsome Therapeutics develops novel therapies for CNS disorders, overlapping with Cyclerion's focus.
Biogen
BIIB
Mkt Cap33.63B
Biogen has a broad portfolio in neurology and neurodegenerative diseases, competing in similar markets as Cyclerion.
Palatin Technologies
PTN
Mkt Cap17.96M
Palatin Technologies works on treatments for diseases with a focus on CNS, posing competition in the therapeutic space.
Alkermes
ALKS
Mkt Cap6.85B
Alkermes has a focus on CNS disorders, including treatments for depression and schizophrenia, competing with Cyclerion's interests.
AMGEN
AMGN
Mkt Cap224.15B
Amgen, with its broad focus, has ventured into CNS treatments, potentially competing with Cyclerion's pipeline.
Abbvie
ABBV
Mkt Cap467.12B
AbbVie has a growing interest in neurology and CNS disorders, directly competing with Cyclerion's research and development focus.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a significant presence in neurology, including Alzheimer's disease, competing in the same therapeutic area as Cyclerion.
Novartis
NVS
Mkt Cap276.48B
Novartis has a diverse portfolio that includes treatments for CNS disorders, making it a competitor.
Pfizer
PFE
Mkt Cap163.41B
Pfizer has a long history in CNS and neurology, including Alzheimer's and depression, competing in the same space as Cyclerion.

About

Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
Show more...
CEO
Jonathan Violin
Employees
1
Country
United States
ISIN
US23255M2044

Listings

XNAS
US
KRSA
BOATS
BOATS
CYCN.BOATS
OTCM
US
CYCN

0 Comments

Share your thoughts

FAQ

What is Cyclerion Therapeutics stock price today?▼
The current price of CYCN is $31.61 USD — it has increased by +32.04% in the past 24 hours. Watch Cyclerion Therapeutics stock price performance more closely on the chart.
What is Cyclerion Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Cyclerion Therapeutics stocks are traded under the ticker CYCN.
Is Cyclerion Therapeutics stock price growing?▼
CYCN stock has risen by +0% compared to the previous week, the month change is a -24.34% fall, over the last year Cyclerion Therapeutics has showed a +37.9% increase.
What is Cyclerion Therapeutics market cap?▼
Today Cyclerion Therapeutics has the market capitalization of 1.44B
When is the next Cyclerion Therapeutics earnings date?▼
Cyclerion Therapeutics is going to release the next earnings report on November 10, 2026.
What were Cyclerion Therapeutics earnings last quarter?▼
CYCN earnings for the last quarter are -3.42 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cyclerion Therapeutics revenue for the last year?▼
Cyclerion Therapeutics revenue for the last year amounts to 2.07M USD.
What is Cyclerion Therapeutics net income for the last year?▼
CYCN net income for the last year is -3.53M USD.
How many employees does Cyclerion Therapeutics have?▼
As of October 02, 2026, the company has 1 employees.
In which sector is Cyclerion Therapeutics located?▼
Cyclerion Therapeutics operates in the Health & Wellness sector.
When did Cyclerion Therapeutics complete a stock split?▼
The last stock split for Cyclerion Therapeutics was on September 09, 2026 with a ratio of 1:7.
Where is Cyclerion Therapeutics headquartered?▼
Cyclerion Therapeutics is headquartered in CAMBRIDGE, United States.